ACQUIRED RESISTANCE TO PD-(L)1 BLOCKADE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0

作者：

Ricciuti, Biagio ^{[1
]}

Lamberti, Giuseppe ^{[1
]}

Alessi, Joao Victor ^{[1
]}

Pecci, Federica ^{[1
]}

Di Federico, Alessandro ^{[1
]}

Wang, Xinan ^{[2
]}

Barrichello, Adriana ^{[1
]}

Vaz, Victor ^{[1
]}

Pangilinan, Andy ^{[1
]}

Haradon, Danielle ^{[1
]}

Elinton, Lee ^{[1
]}

Nishino, Mizuki ^{[3
]}

Rodig, Scott ^{[3
]}

Sholl, Lynette ^{[3
]}

Awad, Mark ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard TH Chan Sch Publ Hlth, Boston, MA USA

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

528

引用

页码：A553 / A554

页数：2

共 50 条

[31] Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Eltahir, Mohamed
Isaksson, Johan
Mattsson, Johanna Sofia Margareta
Karre, Klas
Botling, Johan
Lord, Martin
Mangsbo, Sara M.
Micke, Patrick
CANCERS, 2021, 13 (13)
[32] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
Gonzalez-Velez, Abel
Pino-Villareal, Luis E.
Barrera-Barinas, Alexander
Castillo-Niuman, Andrea
Tolosa-Perez, Erica N.
Castelblanco, Diana, I
Pinzon-Florez, Carlos E.
Yomayusa, Nancy
GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
[33] Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Choi, Jungmin
Sowell, Ryan
Truini, Anna
Schalper, Kurt
Wurtz, Anna
Cai, Guoping
Perry, Curtis
Datar, Ila
Hastings, Katherine
Melnick, Mary Ann
Kaftan, Edward
Kavathas, Paula
Kaech, Susan
Rimm, David
Goldberg, Sarah
Chiang, Anne
Lifton, Richard
Chen, Lieping
Herbst, Roy
Politi, Katerina
Gettinger, Scott
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1331 - S1332
[34] Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
Barba Joaquin, A.
Mosquera, J.
Riudavets Melia, M.
Gomez-Randulfe, M. I.
Garcia Campelo, M. R.
Sullivan, I.
Serra Lopez, J.
Aguado, M.
Piedra, A.
Majem, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1081 - S1081
[35] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
Karachaliou, Niki
Codony-Servat, Jordi
Paulina Bracht, Jillian Wilhelmina
Ito, Masaoki
Filipska, Martyna
Pedraz, Carlos
Chaib, Imane
Bertran-Alamillo, Jordi
Felipe Cardona, Andres
Angel Molina, Miguel
Rosell, Rafael
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
[36] Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC).
Feng, Zheng
Schlichting, Michael
Helwig, Christoph
Chand, Vikram K.
Gelb, Arnold
Jin, Hulin
Grote, Hans Juergen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[37] Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
Ferrara, Roberto
Mezquita, Laura
Texier, Matthieu
Lahmar, Jihene
Audigier-Valette, Clarisse
Tessonnier, Laurent
Mazieres, Julien
Brosseau, Solenn
Leroy, Laura
Duchemann, Boris
Lefebvre, Corentin
Veillon, Remi
Westeel, Virginie
Champiat, Stephane
Planchard, David
Remon, Jordi
Gazzah, Anas
Soria, Jean-Charles
Caramella, Caroline
Besse, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[38] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
Wan, Renping
Zhang, Xiaoni
Qu, Hongyue
Li, Hui
Li, Yingmei
Xu, Mingyan
Xiao, Yun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[39] Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
Min Luo
Fang Wang
Hong Zhang
Kenneth K. W. To
Shaocong Wu
Zhen Chen
Shaobo Liang
Liwu Fu
Signal Transduction and Targeted Therapy, 5
[40] Mitomycin C synergizes with PD-L1 blockade in treatment of non-small cell lung cancer
LUO Min
ZHANG Hong
WU Shao-cong
CHEN Zhen
LIANG Shao-bo
WANG Fang
FU Li-wu
中国药理学与毒理学杂志, 2019, (10) : 885 - 885

← 1 2 3 4 5 →